eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 22
 
Share:
Share:
more
 
 
abstract:
Original paper

The role of N-Myc gene amplification in neuroblastoma childhood tumour – single-centre experience

Przemysław Kaczówka, Aleksandra Wieczorek, Małgorzata Czogała, Teofila Książek, Katarzyna Szewczyk, Walentyna Balwierz

Contemp Oncol (Pozn) 2018; 22 (4): 223-228
Online publish date: 2018/12/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim of the study
Neuroblastoma (NBL) is one of the most common extracranial tumours occurring in children with N-Myc gene amplification, acknowledged as a marker of poor prognosis. We assessed the frequency of N-Myc amplification and its impact on NBL markers and on the treatment outcome.

Material and methods
Among 160 children with NBL treated from 1991 to 2015 in one centre 140 patients had known N-Myc gene status, and they were enrolled in the study. The analysed group was divided into two subgroups: with and without N-Myc amplification (25 and 115 children, respectively). Association of N-Myc amplification with stage of the disease, levels of biochemical parameters, overall survival (OS) and failure-free survival (FFS) were analysed.

Results
The frequency of N-Myc amplification was 17.9%. Most children with N-Myc amplification (64%) were classified to stage 4 NBL. The levels of biochemical markers of NBL: ferritin, dopamine, NSE, and LDH were significantly higher in the group with N-Myc amplification, whereas the levels of VMA and HVA were lower. OS and FFS were significantly lower in children with N-Myc amplification in comparison to children from the control group (OS 53% vs. 76%, p = 0.03; FFS 50% vs. 72%, p = 0.03). The impact of N-Myc amplification on the treatment outcome was significant in patients with stage 4 NBL and children under one year of age.

Conclusions
N-Myc amplification is a crucial prognostic factor in neuroblastoma, which is associated with almost all features related with poor prognosis and a higher probability of unfavourable outcome.

keywords:

neuroblastoma, children, N-Myc gene amplification, treatment outcome

references:
London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cut off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 2005; 23: 6459-6465.
Balwierz W, Szurgot M. Nerwiak zarodkowy współczulny. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Vol. III. Krzakowski M, Warzocha K (eds.). Via Medica 2013; 1082-1098.
Tang XX, Shimada H. Clinical Implications of Neuroblastoma Stem Cells. In: Neuroblastoma. Shimada H (eds.). InTech 2013; 291-302.
Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-480.
Maris JM. Recent advances in neuroblastoma. New Engl J Med 2010; 362: 2202-2211.
Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
Vo KT, Matthay KK, Neuhaus J et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol 2014; 32: 3169-3176.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics. CA Cancer J Clin 2014; 64: 83-103.
Balwierz W, Wieczorek A. New international staging system and classification of risk groups in neuroblastoma. Przegl Lek 2010; 67: 345-349.
Morgernstern DA, Pötschger U, Moreno L, et al. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study. Pediatr Blood Cancer 2018; 65: e27363.
Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009; 100: 1471-1482.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 1985; 313: 1111-1116.
Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d’Oncologie Pédiatrique. J Clin Oncol 1997; 15: 1171-1182.
Okubo T, Knoepfler PS, Eisenman RN, Hogan BL. Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation. Development 2005; 132: 1363-1374.
Wilde BR, Ayer DE. Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis. Br J Cancer 2015; 113: 1529-1533.
Weber A, Imisch P, Bergmann E, Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004; 22: 2681-2690.
Attiyeh EF, London WB, Mossé YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-2253.
Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954-1961.
Spitz R, Betts DR, Simon T, et al. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genet Cytogenet 2006; 167: 51-56.
Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol 2014; 11: 704-713.
Schleiermacher G, Mosseri V, London WB, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer 2012; 107: 1418-1422.
Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 2001; 92: 2451-2461.
Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 2013; 3: a014415.
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-1124.
Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 2001; 92: 2699-2708.
Hann HW, Levy HM, Evans AE. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 1980; 40: 1411-1413.
Nakagawara A, Ikeda K, Tasaka H. Dopaminergic neuroblastoma as a poor prognostic subgroup. J Pediatr Surg 1988; 23: 346-349.
Pang QM, Li K, Ma LJ, Sun RP. Clinical research on neuroblastoma based on serum lactate dehydrogenase. J Biol Regul Homeost Agents 2015; 29: 131-134.
Smith SJ, Diehl NN, Smith BD, Mohney BG. Urine catecholamine levels as diagnostic markers for neuroblastoma in a defined population: implications for ophthalmic practice. Eye (Lond) 2010; 24: 1792-1796.
Nishi M, Miyake H, Takeda T, et al. The relationship between homovanillic/vanillylmandelic acid ratios and prognosis in neuroblastoma. Oncol Rep 1998; 5: 631-633.
Schnepp RW, Maris JM. Targeting MYCN: a good BET for improving neuroblastoma therapy? Cancer Discov 2013; 3: 255-257.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe